Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...
Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?
Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...
Viekira Pak plus ribavirin boasts a hep C cure rate in the low-90% range among those with genotype 1 of virus who are coinfected with HIV.
The U.S. Food and Drug Administration has approved AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with...
AbbVie’s “3D” regimen cured high rates of genotype 1 of hepatitis C virus (HCV) among people coinfected with HIV.
AbbVie’s “3D” regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV, both with a...
AbbVie submitted a new drug application to the FDA for its “3D” combination regimen of antivirals to treat adults with genotype 1 of...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.